CASP3 and Alzheimer disease: Babaei and coworkers [163] employed a similar method for AD induction using the Aβl-42 peptide, which resulted in cognitive impairment, a decline in BDNF, NGF, and Bcl-2 levels, and an increase in Bax and caspase-3 expression (Table 2).